Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis

Reginster, JY; Al Daghri, NM; Bruyere, O

Reginster, JY (reprint author), Liege State Univ, Publ Hlth Epidemiol & Hlth Econ, Quartier Hop, CHU B23,Ave Hippocrate, B-134000 Liege, Belgium.

EXPERT OPINION ON PHARMACOTHERAPY, 2017; 18 (17): 1811

Abstract

The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 mu g daily......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索